Key Dates

Related Announcements

•  August 20, 2021 - Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) - See NOFO PAR 21-282

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this  Notice is to add additional application receipt date in 2024 and extend  the   expiration date for  PAR-21-282 “Blueprint MedTech Translator (U44 - Clinical Trial Optional)”. 

Part 1. Overview Information
Key Dates

Changes in Bold Italic

Application Due Date(s)

October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 20, 2023; October 18, 2023; February 20, 2024, June 20, 2024, September 27, 2024

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

March 2022, July 2022, November 2022, March 2023, July 2023, November 2023, March 2024, July 2024, November 2024, February 2025

Advisory Council Review

May 2022, October 2022, January 2023, May 2023, October 2023, January 2024, May 2024, October 2024, January 2025, May 2025

Earliest Start Date

July 2022; November 2022; March 2023; July 2023; November 2023; March 2024; July 2024; November 2024, March 2025, July 2025

Expiration date: September 28, 2024

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Leonardo Angelone, PhD
National Institute on Drug Abuse (NIDA)
Email: Blueprint-MedTech@nih.gov